Autolus Therapeutics (Autolus Therapeutics) FCF Yield % : -14.76 (As of May. 13, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Autolus Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Autolus Therapeutics's Trailing 12-Month Free Cash Flow is $-156.57 Mil, and Market Cap is $1,061.05 Mil. Therefore, Autolus Therapeutics's FCF Yield % for today is -14.76%.

The historical rank and industry rank for Autolus Therapeutics's FCF Yield % or its related term are showing as below:

AUTL' s FCF Yield % Range Over the Past 10 Years
Min: -73.91 Med: -29.84 Max: -2.76
Current: -14.76

During the past 8 years, the highest FCF Yield % of Autolus Therapeutics was -2.76%. The lowest was -73.91%. And the median was -29.84%.

AUTL's FCF Yield % is ranked better than
50.13% of 1556 companies
in the Biotechnology industry
Industry Median: -14.17 vs AUTL: -14.76

Autolus Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

Autolus Therapeutics FCF Yield % Historical Data

The historical data trend for Autolus Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Autolus Therapeutics FCF Yield % Chart

Autolus Therapeutics Annual Data

Trend

Sep16

Sep17

Sep18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

Get a 7-Day Free Trial

-20.24

-28.30

-26.86

-37.45

-13.96

Autolus Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Yield %	Get a 7-Day Free Trial															-18.49	-57.83	-41.16	-41.14	-9.39

Competitive Comparison of Autolus Therapeutics's FCF Yield %

For the Biotechnology subindustry, Autolus Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Autolus Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Autolus Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Autolus Therapeutics's FCF Yield % falls into.

Autolus Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Autolus Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-156.573	/	1121.21044
	=	-13.96%

Autolus Therapeutics's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-26.31	*	4	/	1121.21044
	=	-9.39%

Autolus Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Autolus Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Autolus Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Autolus Therapeutics (Autolus Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Autolus Therapeutics PLC (NAS:AUTL) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

6A3A:Germany

Address

191 Wood Lane, The MediaWorks, London, GBR, W12 7FP

Website

https://www.autolus.com

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.